ArticleMaterials today. Bio2026
A renally clearable tumor-targeted probe enabling functional delineation of tumor margins by NIR-II fluorescence lifetime imaging.
Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accurate intraoperative delineation of tumor margins remains a major clinical challenge because conventional fluorescence imaging is strongly influenced by probe concentration, tissue heterogeneity, and imaging conditions. Here, we report a renally clearable, tumor-targeted molecular probe, NY-07, for quantitative tumor-margin delineation using second near-infrared (NIR-II) fluorescence lifetime (FLT) imaging. NY-07 is constructed by conjugating a cyanine-based fluorophore with pemetrexed as an active targeting ligand, yielding a clinically compatible probe with excellent solubility, high optical stability, and efficient renal clearance. NY-07 exhibits tail emission in the NIR-II window with a stable fluorescence lifetime of 480 ± 0.6 ps and NIR-II brightness approximately twice that of indocyanine green (ICG) at the same concentration, while retaining ∼70% of its NIR-II signal after 7 days of storage. In vivo imaging demonstrates rapid renal excretion, with strong kidney and bladder signals within seconds after injection and minimal hepatic accumulation. Using cell models, tumor-bearing mice, and patient-derived tissues, we show that NY-07 enables target-specific NIR-II FLT imaging and achieves quantitative discrimination between tumor, inflammation, and normal tissues based on distinct lifetime signatures, enabling precise visualization of tumor margins independent of probe concentration and imaging parameters. Compared with conventional NIR-II fluorescence intensity (FLI) imaging, FLT imaging significantly reduces false-positive signals and improves boundary definition in complex biological environments. This work establishes a clinically translatable strategy that integrates renal clearance, active tumor targeting, and lifetime-resolved imaging for functional tumor-margin delineation, providing a robust platform for improving surgical precision and advancing next-generation image-guided oncologic surgery.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.